Case report and literature review on AML with t(7;21)(p22;q22) and 5q abnormality.
Survival
Date of diagnosis: 02-2013 Treatment Following diagnosis, the patient was seen at an outside institution for treatment and was placed on Revlimid therapy as opposed to induction chemotherapy for about 5 months without improvement or significant deterioration of her blood counts. She was referred to our institution to be evaluated for allogenic stem-cell transplantation. A repeat bone marrow biopsy (~6-7 months post diagnosis) confirmed persistent AML, and the cytogenetic studies were performed. The patient was then started on 7+3 AML induction (Cytarabine 320 mg IV continuous days 1-7, Idarubicin 19 mg IV on days 3-6). A day 16 repeat bone marrow biopsy showed persistent presence of abnormal myeloblasts. Biopsy about 6 weeks following induction therapy showed remission with no excess or abnormal myeloblasts. She was subsequently admitted and completed her first cycle of consolidation chemotherapy with high-dose cytarabine (3 gm/m2 IV q 12 hours on days 1, 3, 5 for 6 doses). 
Other Molecular Studies
Technics: DNA was isolated by routine methods and subjected to quantitative real-time polymerase chain reaction using allele-specific primers complementary to the mutated and wild-type sequences of the JAK2 gene.
Results:
Negative for JAK2 mutation V617F.
Other Findings

Note:
The previous FISH studies on G-banded metaphases showed that the AML1 signal was split and moved to 7p, and the subtelomeric probes for 7p/q showed that the 7p signal moved to 21q, thus, establishing the t(7;12).
The sequential FISH study on a previously G-banded metaphase with LSI RUNX1/RUNXT1 probe showing the green signals of RUNX1 on der(7), der(21) and normal chromosome 21, respectively. Two normal orange of RUNXT1 are seen on the chromosomes 8.
FISH with TelVysion 7p (green, on the sub-telomere region of 7p), 7q (orange, on the sub-telomere region of 7q) and chromosome 14 (yellow and aqua) showing one green signal of 7p on der(21), and the der (7) is missing a green signal. Two normal chromosomes 14 are seen as indicated by the signal pattern (one yellow and one aqua signals on two normal chromosomes 14 respectively).
Comments
We present a new case of AML, NOS with monocytic differentiation (myelomonocytic leukemia) which was shown to carry a cryptic t(7;21)(p22;q22) and 5q loss. The cryptic translocation t(7;21)(p22;q22) involving RUNX1 and presumably USP42 is a rare recurrent abnormality in AML (Paulsson et al., 2006) and shows association with 5q abnormalities. RUNX1 codes for a transcription factor in the 'Runt domain' gene family and is a regulator of hematopoiesis. The gene USP42 is involved in the ubiquitin pathway, and is fused to the 3' region of the RUNX1 gene in this translocation. A recent study evaluated 397 consecutive AML patients with RUNX1 FISH probes and identified 3 patients with t(7;21)(p22;q22), suggesting a relative incidence in about 1% of AML cases (Jeandidier et al., 2012) . Nine previously reported cases have been identified on literature review (see references below) with a broad age of onset (7-68 years, median 39), many with monocytic differentiation, frequently aberrant immunophenotypic antigen expression (often with CD7 and/or CD56), and generally poor response to induction chemotherapy. Long term survival data are limited at present. Our presented case also had evidence of persistent leukemia after 6 months of initial treatment with Revlimid (at another institution), but achieved complete remission by morphology, flow, and cytogenetics after standard 7+3 AML induction chemotherapy. She has since completed her first cycle of consolidation chemotherapy (high-dose Cytarabine) without incident. She is alive and in remission as of 9 months from diagnosis.
